.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Abstract talk
O 013

Fusion inhibitory peptides protect against SARS-CoV-2 Omicron BA.5 transmission in hamsters

Appointment

Date: 25/03/2024

Time: 15:45 – 16:00

Talk time: 12 Min.

Discussion time: 3 Min.

Location / Stream:

Lecture hall 3

Session

Antiviral therapy and resistance 1

Topic

Antiviral therapy and resistance

Authors

Kim Handrejk (Rotterdam / NL), Katharina S. Schmitz (Rotterdam / NL), Melanie Rissmann (Rotterdam / NL), Laura L. A. van Dijk (Rotterdam / NL), Edwin J. B. Veldhuis Kroeze (Rotterdam / NL), Peter van Run (Rotterdam / NL), Amitava Chandra (Ithaca, NY / US), Victor K Outlaw (Wisconsin, WI / US), Samuel H. Gellman (Wisconsin, WI / US), Anna Mykytyn (Rotterdam / NL), Bart L. Haagmans (Rotterdam / NL), Christopher A. Alabi (Ithaca, NY / US), Anne Moscona (New York, NY / US), Dr. Rik L. de Swart (Rotterdam / NL), Dr. Rory D. de Vries (Rotterdam / NL), Mattteo Porotto (Caserta / IT; New York, NY / US)